Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics
Authors:
- 25 May 2016
- journal article
- research article
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 18 (4) , 581-592
Abstract
Huntington’s disease (HD) is a devastating neurodegenerative disease caused by the pathological elongation of the CAG repeats in the huntingtin gene. Caloric restriction (CR) has been the most reproducible environmental intervention to improve health and prolong life span. We have demonstrated that CR delayed onset and slowed disease progression in a mouse model of HD. Metformin, an antidiabetic drug, mimics CR by acting on cell metabolism at multiple levels. Long-term administration of metformin improved health and life span in mice. In this study, we showed that metformin rescued cells from mutant huntingtin (HTT)-induced toxicity, as indicated by reduced lactate dehydrogenase (LDH) release from cells and preserved ATP levels in cells expressing mutant HTT. Further mechanistic study indicated that metformin activated AMP-activated protein kinase (AMPK) and that inhibition of AMPK activation reduced its protective effects on mutant HTT toxicity, suggesting that AMPK mediates the protection of metformin in HD cells. Furthermore, metformin treatment prevented mitochondrial membrane depolarization and excess fission and modulated the disturbed mitochondrial dynamics in HD cells. We confirmed that metformin crossed the blood–brain barrier after oral administration and activated AMPK in the mouse brain. Our results urge further evaluation of the clinical potential for use of metformin in HD treatment.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS082338)
- National Cancer Institute (CA006973)
- National Center for Advancing Translational Sciences (TR001079)
This publication has 29 references indexed in Scilit:
- Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fissionDrug Discovery Today, 2014
- The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitroNeurobiology of Disease, 2014
- AMP‐activated protein kinase counteracts brain‐derived neurotrophic factor‐induced mammalian target of rapamycin complex 1 signaling in neuronsJournal of Neurochemistry, 2013
- Impaired Mitochondrial Dynamics and Nrf2 Signaling Contribute to Compromised Responses to Oxidative Stress in Striatal Cells Expressing Full-Length Mutant HuntingtinPLOS ONE, 2013
- Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.2013
- Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cellsBone, 2013
- Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's diseaseHuman Molecular Genetics, 2011
- Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharidePharmacological Reports, 2010
- Calorie restriction mimetics: an emerging research fieldAging Cell, 2006
- Regulation of mitochondrial fission and apoptosis by the mitochondrial outer membrane protein hFis1Journal of Cell Science, 2005